

The CytoTools AG prevails in judicial approval proceedings before the Higher Regional Court, Frankfurt am Main

- The Higher Regional Court (Oberlandesgericht, OLG) Frankfurt am Main decided that the lawsuit of the defendant against the resolution of the AGM, dated 10th August 2017, regarding agenda item 6, does not preclude the completed entry in the commercial register.
- The further realization of the convertible bond issue program for the financing of clinical trials and other projects can thus continue as planned.

Darmstadt, 23rd February 2018 – The CytoTools AG has been successful with its application for approval in front of the OLG in Frankfurt am Main. The resolution of the AGM, dated 10th August 2017, is entered in the commercial register and the lawsuit does not prevent this. Therefore, the entry remains as it is, unaffected by the lawsuit.

The company has made use of the possibility of summary approval proceedings, acc. to § 246a AktG (German Stock Corporation Act). The proceedings took place at the OLG Frankfurt am Main which made the decision in mid February 2018 as follows: „It is concluded that the action at the OLG Frankfurt am Main, brought by the defendant against the petitioner's resolution, regarding agenda item 6 at the AGM, dated 10th August 2017, does not preclude the completed entry in the commercial register, and that shortcomings of the resolution do not impinge upon the effectiveness of the entry.”

The CytoTools AG has made a contract for the issue of convertible bonds up to a total of 15 million EUR for the financing of clinical trials and further developments. After the decision of the OLG in Frankfurt, there is now a secure basis for the issue of further convertible bonds and the realization of our plans without delay.

This information contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (58%) and CytoPharma GmbH (47%).

Contact:

CytoTools AG
Dr. Mark-André Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de